Herbal supplement (adaptogen)
Tongkat Ali
In mice and rats, eurycomanone, a major compound of tongkat ali, had an elimination half-life of 0.30 h after intravenous dosing; the app lists 4 h, and no human half-life was identified.1
Tongkat Ali after one dose: 50% at ~4 h, 25% at 8 h, 12.5% at 12 h.
Drawn from the half-life in the app's model, ~4 h. The model's figures
- Compound
- Tongkat Ali
- Symbol
- TKA
- Family
- Supplements
- Parts
- 13
- References
- 13
- Checked
- Last reviewed . Sources are listed below.
Overview
Tongkat ali is the common name of Eurycoma longifolia Jack, which Leisegang and colleagues (Medicina, 2022) describe as traditionally used for management of male sexual dysfunction and infertility.2 The app files it as an adaptogen supplement, with the synonyms tongkat and longjack.
Most of the trials described below used one product, Physta, a standardised water extract of the root made by Biotropics Malaysia Berhad and specified at 0.8–1.5% eurycomanone.3,2
The European Food Safety Authority's panel concluded in 2021 that the safety of a standardised tongkat ali root extract "has not been established under any condition of use".4 The Norwegian Food Safety Authority states that tongkat ali is not permitted as a food or dietary supplement in Norway or the EU.5
The app grades the evidence as moderate. Two of the trials below were funded by Biotropics Malaysia, the supplier of Physta.3,6
How it works
Talbott and colleagues (Journal of the International Society of Sports Nutrition, 2013) write that "The precise mechanism by which eurypeptides or tongkat ali root extract restores normal testosterone levels is unknown".6 Leisegang and colleagues report that animal studies showed higher release of luteinizing hormone and follicle-stimulating hormone gonadotropins, and that there may be inhibition of the aromatase enzyme.2 In 32 healthy young men taking 600 mg/day for two weeks, Chan and colleagues (Andrologia, 2021) reported significant interaction and time effects for testosterone, free testosterone and estradiol in favour of the treatment group, while luteinising hormone, follicle-stimulating hormone and sex hormone-binding globulin did not.7 The authors wrote that the lack of change in the two gonadotropins "suggests that a lesser role played by Eurycoma longifolia in activating the hypothalamic-pituitary-gonadal axis in the young adults".7 The app's notes say tongkat ali lowers SHBG; in the trial of Chinnappan and colleagues, "There were no significant changes in SHBG", and the meta-analysis reports that "six out of nine studies reported no significant variation in SHBG levels after treatment".3,2
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~4 h
- Bioavailability
- 50%
- Typical dose
- 200–400 mg/day
- Route
- Oral
- Time to peak
- ~2 h
Sources in this part
The one study in the sources that measured eurycomanone in plasma dosed eurycomanone, which its authors call the plant's major chemical compound, to mice and rats, not to people.1 The authors state that the rat and mouse values "cannot be directly extrapolated to humans", and EFSA repeats that the values "may not be directly extrapolated from rodents to humans".1,4
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~4 h | Eurycomanone elimination half-life of 0.30 h after 1 mg/kg intravenously in mice and 0.30 h after 3 mg/kg intravenously in rats; for eurycomanone from a standardised water extract given at 10 mg/kg intravenously to rats, 0.12 h in the results text and 0.11 h in the source's Table 2; no human value identified1 |
| Bioavailability | 50% | Oral eurycomanone bioavailability of 54.9% in mice (10 mg/kg) and 11.8% in rats (30 mg/kg); after the standardised extract was given orally to rats at 100 mg/kg, eurycomanone was undetectable in plasma1 |
| Time to peak | ~2 h | Observed Tmax of 2 h after oral eurycomanone in mice and rats1 |
| Interaction flags | None listed | In 14 healthy young men, 200 mg of a water-based extract taken with a single oral 80 mg dose of propranolol was followed by a 29% lower propranolol AUC, a 42% lower Cmax and a Tmax prolonged by almost 86%, with the terminal elimination half-life not significantly affected8 |
The pharmacokinetic study sampled plasma for 8 h only, and its authors note that this "limits the window of analysis" for a second concentration peak.1 It was funded by the Malaysian Ministries of Agriculture and of Health, and its authors state that "There are no competing financial interests in this study".1 No human pharmacokinetic study of tongkat ali extract or eurycomanone was identified among the 10 PubMed records returned for "eurycomanone pharmacokinetics", so the app's 4 h, 50% and 2 h have no human figure beside them.1
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Chinnappan and colleagues, Food and Nutrition Research, 20213 | Double-blind, placebo-controlled, randomised phase II trial at two Indian hospitals; funded by Biotropics Malaysia Berhad3 | 105 men aged 50–70 y with total testosterone below 300 ng/dL, 35 per group3,2 | Physta 100 mg, 200 mg or placebo daily; 12 weeks3 | Total testosterone at week 12: 203.8 ± 54.6 ng/dL (100 mg), 225.0 ± 49.8 (200 mg), 177.9 ± 43.7 (placebo); no significant between-group difference in free testosterone; no significant change in SHBG; 8 adverse events, no serious ones3 |
| Leitão and colleagues, Maturitas, 20219 | Randomised, double-blind, placebo-controlled, four arms: control or concurrent training, each with extract or placebo9 | 45 men, mean age 47.38 ± 5.03 y, with androgen deficiency of the aging male9 | 200 mg of extract or placebo, with or without concurrent training 3 times a week for 60 min; 6 months9 | Erectile function improved in both interventions, most with training plus extract; the meta-analysis table lists testosterone (ng/dL) of 278.2 ± 20.5 before and 400.3 ± 38.9 after on 200 mg (n = 9, patients with ADAM aged 40–59 y) against 281.5 ± 17.7 before and 258.5 ± 33.7 after in controls (n = 12), p < 0.05, and notes that no statistical comparison was provided between concurrent training with placebo and concurrent training with extract9,2 |
| Chan and colleagues, Andrologia, 20217 | Placebo-controlled, double-blind, matched-pair7 | 32 healthy males, mean age 24.4 ± 4.7 y7 | 600 mg/day or placebo; 2 weeks7 | Significant interaction and time effects for testosterone (p = .005), free testosterone (p = .012) and estradiol (p = .008) in favour of the treatment group; LH, FSH and SHBG did not7 |
| Talbott and colleagues, Journal of the International Society of Sports Nutrition, 20136 | Randomised, look-alike placebo; funded by Biotropics Malaysia and run by SupplementWatch6 | 63 moderately stressed adults completed (32 men, 31 women)6 | Physta 200 mg/day or placebo; 4 weeks6 | Salivary cortisol 16% lower and salivary testosterone 37% higher than placebo; Tension 11%, Anger 12% and Confusion 15% lower; no effect on Depression, Vigor or Fatigue; three people reported unusual fatigue (two on tongkat ali, one on placebo)6 |
| Chen and colleagues, International Journal of Preventive Medicine, 201910 | Randomised, placebo-controlled; four groups (extract, resistance training, both, control)10 | 40 young males10 | 200 mg/day or placebo; 8 weeks10 | No significant difference in urinary testosterone:epitestosterone ratio between pre- and posttests in any group; no change in isokinetic strength or average power in the control and extract-only groups; the authors report that resistance training, with or without the extract, improved isokinetic power of the lower limb, and that the combined group improved peak power output10 |
| George and colleagues, Phytotherapy Research, 201611 | Randomised, double-blind, placebo-controlled, parallel; authors from Biotropics Malaysia11 | 84 middle-aged Japanese adults with relatively lower immune scores; 83 completed11 | 200 mg/day Physta or rice powder placebo; 4 weeks11 | Scoring of Immunological Vigor and immunological grade higher with tongkat ali at week 4; no severe adverse events (testosterone not the outcome)11 |
| Leisegang and colleagues, Medicina, 20222 | Systematic review; meta-analysis of 5 randomised trials; no external funding2 | Men in 9 studies published 2012–2021; 5 trials in the pooled analysis2 | Doses of 100 to 600 mg/day, 3 days to 6 months2 | Pooled total testosterone SMD 1.352 (95% CI 0.565 to 2.138, p = 0.001); inconsistency 87.27%; Begg test p = 0.0243, indicating publication bias2 |
Deeper analysis: Chinnappan and colleagues, 2021
Chinnappan and colleagues, from Biotropics Malaysia Berhad and two Indian hospitals, reported in Food and Nutrition Research (2021) what they describe as a "double-blind, placebo-controlled, multicentre, randomised, phase II clinical trial with a 12-week safety and efficacy monitoring period".3 The 105 men who completed it were healthy volunteers with testosterone below 300 ng/dL, and "The primary endpoints were changes in serum total and free testosterone levels".3,2
Total testosterone rose from 187.3 ± 46.4 to 203.8 ± 54.6 ng/dL on 100 mg, from 200.5 ± 46.4 to 225.0 ± 49.8 ng/dL on 200 mg, and fell from 183.0 ± 37.8 to 177.9 ± 43.7 ng/dL on placebo.3 The difference from placebo was significant at week 12 for 100 mg and from week 4 for 200 mg, while the 200 mg group also started about 17 ng/dL above placebo.3 There was no significant between-group difference in free testosterone at any time point, although both Physta groups rose within-group.3 Ageing Male Symptoms scores at week 12 were 26.71 ± 8.986 on 200 mg and 58.06 ± 13.22 on placebo, and "No significant within-group changes were observed in the placebo group for AMS and FSS scores".3 Among other secondary results, SHBG did not change, DHEA showed no significant between-group change, and cortisol did not differ from placebo at week 12, though it fell within the 200 mg group.3 On safety, "A total of eight AEs occurred during the study but there were no SAEs", with gastrointestinal symptoms in three people on 100 mg and three on 200 mg, itching in one person on 200 mg and fever in one on placebo; "all AEs were resolved by the end of the study".3 The authors describe Physta as "safe and well tolerated in the study population".3 The authors list limitations: "this study has the limitation of involving a small number of subjects", and "Daily food intake, exercise regime and other lifestyle details of the subjects were not collected in the study".3 Biotropics Malaysia Berhad funded the study, and two authors, S.M.C. and A.G., are its employees.3
Deeper analysis: Talbott and colleagues, 2013
Talbott and colleagues randomised 64 volunteers recruited in and around Salt Lake City, Utah, to 200 mg/day of Physta or look-alike placebo for 4 weeks, and 63 completed.6 Hormone and mood results are reported for the 63 men and women together; salivary cortisol was 16% lower, salivary testosterone 37% higher and the cortisol:testosterone ratio 36% lower than on placebo.6 Mood results were mixed: Tension, Anger and Confusion improved compared with placebo, there was "no effect observed between supplementation groups for indices of Depression, Vigor, or Fatigue", and the trend for global mood (+3%, p = .083) was not significant.6 Liver enzymes, body weight and body fat percentage did not change significantly, and "Three subjects reported feeling unusually fatigued during the first two weeks of the study (two subjects in the TA group and 1 subject in the placebo group)".6 The article has no limitations section among its headings (Background, Methods, Results, Discussion, Conclusions).6 Funding was from Biotropics Malaysia, and the competing-interests statement says one author "is an employee of a company that manufactures tongkat ali extract" and another "is an employee of a nutrition company that uses tongkat ali as one ingredient in an anti-stress dietary supplement"; two authors conducted the study as employees of SupplementWatch.6
Deeper analysis: Leisegang and colleagues, 2022 meta-analysis
Leisegang and colleagues searched PubMed, Scopus, Web of Science, Cochrane, Ovid/Embase and Google Scholar on 10 July 2021 for trials of E. longifolia as a sole intervention in adult males that reported testosterone, and the review included nine studies, five of them randomised trials in the meta-analysis.2 Most studies reported a significant improvement in total testosterone, but "two studies failed to observe any improvement in testosterone levels when the treatment was stopped after 3 weeks or prolonged to 8 weeks", and "Ismail et al. and George et al. did not report any difference when healthy married men were treated".2 The pooled result was an SMD of 1.352 (95% CI 0.565 to 2.138, p = 0.001), with heterogeneity of 87.27% and a Begg test p value of 0.0243 that the authors say indicates publication bias.2 In the subgroup split, testosterone rose in men with and without hypogonadism "although the increase was significant in the hypogonadism group".2 Of the five trials, "some showed low (n = 2) or high (n = 1) risk of bias".2 The authors list their limitations: "First and foremost, the analysis was based on five studies, which were heterogeneous in terms of study design, included population, dosage and length of treatment, and limited sample sizes".2 They report no external funding and no conflict of interest.2 Their conclusion is that more research "is required before its use in clinical practice", while the EFSA panel separately concluded that safety of one extract had not been established.2,4
Smaller trials in the table
Leitão and colleagues (Maturitas, 2021) name their main limitation as "the study not having groups that used only Eurycoma longifolia and only concurrent training", and the PubMed record states no funder.9 Chen and colleagues (2019) report no conflicts of interest and thank Biotropics Malaysia Berhad for "supplying the supplements and placebo for this study".10 George and colleagues (2016) include authors from Biotropics Malaysia Berhad, and the PubMed record lists the publication type "Research Support, Non-U.S. Gov't" without naming a funder.11 The PubMed record for Chan and colleagues (Andrologia, 2021) lists the grant "University of Malaya post graduate PG241-2016A".7
Doses reported in studies and on labels
The app lists a typical dose of 200–400 mg/day, and the sources report these doses.
| Setting | Dose reported | Length and people | Reference |
|---|---|---|---|
| Physta, men aged 50–70 y with low testosterone | 100 mg or 200 mg daily | 12 weeks; 35 per group | Chinnappan and colleagues, 20213 |
| Physta, moderately stressed adults | 200 mg/day | 4 weeks; 63 completed | Talbott and colleagues, 20136 |
| Extract, men with androgen deficiency of the aging male | 200 mg | 6 months; 45 men randomised | Leitão and colleagues, 20219 |
| Extract, healthy young men | 600 mg/day | 2 weeks; 32 men | Chan and colleagues, 20217 |
| Extract, young men with or without resistance training | 200 mg daily | 8 weeks; 40 men | Chen and colleagues, 201910 |
| Physta, male cyclists aged 57–72 y (study tabulated in the meta-analysis) | 400 mg | 3 weeks, then 5 weeks; 13 men | Henkel and colleagues, 2014, as listed by Leisegang and colleagues, 20222 |
| Proposed food supplement use, adults other than pregnant and lactating women | Up to 200 mg/day of a standardised water extract | Proposal by the applicant, Biotropics Malaysia Berhad | EFSA opinion, 20214 |
| Typical dosage range stated in the background of a trial paper | 50–200 mg/day of a water-extracted root standardised to 22% eurypeptides | Statement in the paper's background | Talbott and colleagues, 20136 |
The app's upper figure of 400 mg/day is above the 200 mg/day that EFSA records as proposed for a standardised extract.4 No dosing label for tongkat ali was identified: the one DailyMed record returned for "Eurycoma longifolia" is a multi-ingredient capsule.
Side effects reported
Leisegang and colleagues state that "Only one study reported adverse effects associated with E. longifolia treatment", which included gastrointestinal symptoms and itching, "while Ismael et al. observed adverse events in both treated and placebo groups".2 Chinnappan and colleagues recorded eight adverse events and no serious ones in 105 men over 12 weeks, with gastrointestinal symptoms in six, itching in one on 200 mg and fever in one on placebo.3 Talbott and colleagues reported unusual fatigue in three of 63 people during the first two weeks (two on tongkat ali, one on placebo) and "no other adverse events or side effects".6 George and colleagues stated that "No severe adverse events were observed" in 83 completers over 4 weeks.11 EFSA notes that the human studies of E. longifolia extracts "were primarily designed to investigate putative beneficial effects of the NF and addressed only a limited number of safety endpoints".4 In laboratory and animal tests of a standardised water extract, EFSA reported no biologically relevant increase in revertant colonies in a bacterial reverse mutation test, no clastogenic or aneugenic effect in a mouse micronucleus assay given intraperitoneally, a dose-dependent increase in aberrant cells in cultured human lymphocytes, and a positive comet assay in rat stomach and duodenum at 2,000 mg/kg body weight.4 The Panel concluded that the extract "has the potential to induce DNA damage, which is of concern, particularly locally for tissues that represent first sites of contact", and judged the likelihood of allergic reactions to be low.4 Talbott and colleagues also write that some supplements labelled as Eurycoma longifolia contain "none of the actual root" and are spiked with prescription erectile dysfunction drugs, including tadalafil, sildenafil and vardenafil.6
Bloodwork and markers
The app lists total testosterone, free testosterone, SHBG and cortisol as markers to monitor.
Total testosterone: higher than placebo at week 12 on 100 mg and 200 mg in men with low baseline levels, and in the pooled meta-analysis; in healthy men, Chan and colleagues reported significant interaction and time effects on 600 mg/day for two weeks, while two trials in healthy men found no difference.3,2,7
Free testosterone: no significant between-group difference in Chinnappan and colleagues, a significant interaction effect in Chan and colleagues, and a 37% higher salivary level in Talbott and colleagues.3,7,6
SHBG: no significant change in Chinnappan and colleagues and in Chan and colleagues, and no significant variation in six of nine studies in the meta-analysis.3,7,2
Cortisol: 16% lower in saliva than placebo in moderately stressed adults on 200 mg/day for 4 weeks, but not significantly different from placebo at week 12 in men with low testosterone on 100 mg or 200 mg.6,3
Regulatory and anti-doping status
The Norwegian Food Safety Authority (Mattilsynet) states that using tongkat ali as food or as a dietary supplement is not permitted.5 It says the plant is on the EU novel food status listing, so that sale in the EU or Norway (EEA) is not permitted, and that the listing applies to all parts of the plant.5 The EFSA Panel on Nutrition, Novel Foods and Food Allergens published its opinion in the EFSA Journal in December 2021 on a standardised water extract of the root, for which Biotropics Malaysia Berhad was the applicant.4 The extract was proposed for use as a food supplement in amounts up to 200 mg/day in adults other than pregnant and lactating women, with eurycomanone at 0.8–1.5%, and EFSA notes it "has been present in various international markets since 2009".4 The 2026 WADA Prohibited List, in force from 1 January 2026, does not name Eurycoma longifolia, tongkat ali or longjack in its text.12 Chen and colleagues found no significant change in the urinary testosterone:epitestosterone ratio after 8 weeks of 200 mg/day, with all ratios "below the threshold limit of 4:1 that was set as the cut-off ratio by IOC".10 A DailyMed search for "Eurycoma longifolia" returned one label, for a multi-ingredient capsule, and no single-ingredient tongkat ali label was identified; documents from the US FDA, TGA and Health Canada on tongkat ali were not retrieved.
What is not known
No human pharmacokinetic study of eurycomanone or tongkat ali extract was identified in the PubMed records returned for "eurycomanone pharmacokinetics", so a human half-life, bioavailability and time to peak are not established in the sources.1 Most trials used one manufacturer's extract, and three trials in the table were funded or supplied by that manufacturer.2,3,6,10 Results in healthy men are mixed: Chan and colleagues reported significant effects at 600 mg/day, two trials reported no difference, and the meta-analysis states that the increase was significant in the hypogonadism group.7,2 EFSA's conclusion that safety "has not been established under any condition of use" rests on genotoxicity findings from laboratory and animal tests of one extract, and the human trials examined only a limited set of safety endpoints.4 A registered phase II trial of a tongkat ali and maca herbal product in men (NCT05347329, sponsor Natural Wellness Egypt) has the status COMPLETED; as a combination, its result could not be read as that of tongkat ali alone, and no results were retrieved for it.13
Frequently asked questions
What is the half-life of tongkat ali?
What is the bioavailability of tongkat ali?
Is tongkat ali banned by WADA?
Is tongkat ali legal in the EU?
Does tongkat ali raise testosterone?
A meta-analysis of five randomised trials reported a pooled standardised mean difference of 1.352 (95% CI 0.565 to 2.138, p = 0.001) for total testosterone, with inconsistency of 87.27% and a Begg test indicating publication bias.2 In men with testosterone below 300 ng/dL, 200 mg/day of Physta for 12 weeks gave 225.0 ± 49.8 ng/dL against 177.9 ± 43.7 on placebo, and free testosterone did not differ significantly between groups.3 Biotropics Malaysia Berhad funded that trial, and two of its authors are employees of the company.3
Does tongkat ali lower SHBG?
The app's notes say it does, but Chinnappan and colleagues reported "no significant changes in SHBG" at 100 mg and 200 mg daily for 12 weeks.3
Does tongkat ali lower cortisol?
What side effects were reported in tongkat ali trials?
Chinnappan and colleagues recorded eight adverse events and no serious ones among 105 men over 12 weeks, mostly gastrointestinal symptoms.3 EFSA noted that the human studies addressed only a limited number of safety endpoints and reported genotoxicity signals in laboratory and animal tests of one extract.4
Does tongkat ali interact with propranolol?
In 14 healthy young men, 200 mg of a water-based extract taken with propranolol was followed by a 29% lower propranolol AUC and a 42% lower Cmax.8
Guides, tools and comparisons
References
- Ahmad N, et al. Bioavailability of Eurycomanone in Its Pure Form and in a Standardised Eurycoma longifolia Water Extract. Pharmaceutics 2018. PMID 29997335
- Leisegang K, et al. Eurycoma longifolia (Jack) Improves Serum Total Testosterone in Men: A Systematic Review and Meta-Analysis of Clinical Trials. Medicina (Kaunas) 2022. PMID 36013514
- Chinnappan SM, et al. Effect of Eurycoma longifolia standardised aqueous root extract-Physta on testosterone levels and quality of life in ageing male subjects: a randomised, double-blind, placebo-controlled multicentre study. Food Nutr Res 2021. PMID 34262417
- EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). Safety of Eurycoma longifolia (Tongkat Ali) root extract as a novel food pursuant to Regulation (EU) 2015/2283. EFSA J 2021;19(12):e06937. EFSA opinion
- Mattilsynet (Norwegian Food Safety Authority). Tongkat Ali er ikke tillatt i Norge. Published 10 January 2025. Mattilsynet page
- Talbott SM, et al. Effect of Tongkat Ali on stress hormones and psychological mood state in moderately stressed subjects. J Int Soc Sports Nutr 2013. PMID 23705671
- Chan KQ, et al. The effect of Eurycoma Longifolia on the regulation of reproductive hormones in young males. Andrologia 2021. PMID 33559971
- Salman SA, et al. Modification of propranolol's bioavailability by Eurycoma longifolia water-based extract. J Clin Pharm Ther 2010. PMID 21054461
- Leitão AE, et al. A 6-month, double-blind, placebo-controlled, randomized trial to evaluate the effect of Eurycoma longifolia (Tongkat Ali) and concurrent training on erectile function and testosterone levels in androgen deficiency of aging males (ADAM). Maturitas 2021. PMID 33541567
- Chen CK, et al. Effects of Eurycoma Longifolia Jack Supplementation Combined with Resistance Training on Isokinetic Muscular Strength and Power, Anaerobic Power, and Urinary Testosterone: Epitestosterone Ratio in Young Males. Int J Prev Med 2019. PMID 31367282
- George A, et al. Immunomodulation in Middle-Aged Humans Via the Ingestion of Physta Standardized Root Water Extract of Eurycoma longifolia Jack. Phytother Res 2016. PMID 26816234
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list
- Natural Wellness Egypt. A Clinical Trial to Investigate the Efficacy and Safety of Tongkat Ali Maca Plus. ClinicalTrials.gov NCT05347329. NCT05347329